Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database
Objective Efgartigimod alfa is an important novel drug for the treatment of myasthenia gravis. However, postmarketing safety data for this drug is limited, underscoring the need for comprehensive safety evaluations in real-world populations.Design and setting This study aims to identify adverse even...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/7/e095652.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|